

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

**CLARIFICATION ANNOUNCEMENT
REVISED PROXY FORM FOR USE AT THE AGM
TO BE HELD ON 30 MAY 2024**

References are made to the notice of annual general meeting (the “**AGM Notice**”) of China Resources Pharmaceutical Group Limited (the “**Company**”), the circular (the “**Circular**”) and the proxy form (the “**Original Proxy Form**”), each dated 26 April 2024, for the annual general meeting of the Company to be held at 50th Floor, China Resources Building, 26 Harbour Road, Wanchai, Hong Kong on Thursday, 30 May 2024 at 3:30 p.m. (the “**AGM**”) and any adjournment thereof.

The Company wishes to clarify that there are inadvertent clerical errors in the Chinese version of the Original Proxy Form whereas:

- (i) the ordinary resolution numbered 3(4) thereof should be read as “(4) 重選白曉松先生為董事。”; and
- (ii) the ordinary resolution numbered 3(5) thereof should be read as “(5) 重選陶然先生為董事。”.

For this reason, a revised proxy form (the “**Revised Proxy Form**”) for the AGM (or any adjournment thereof) are published on the websites of The Stock Exchange of Hong Kong Limited and the Company on 28 May 2024 along with this announcement.

The date, time and address for holding the AGM remain unchanged. The content of the ordinary resolutions numbered 3(4) and 3(5) have been correctly stated in the AGM Notice, the Circular, and the English version of the Original Proxy Form. The English version of the Original Proxy Form does not carry the above clerical error, and all information and content of the English version of the Original Proxy Form remain unchanged.

Save for the aforementioned clarification, all information and content of the Chinese version of the Original Proxy Form remain unchanged. This announcement is supplemental to and should be read in conjunction with the AGM Notice, the Circular, and the Original Proxy Form.

Shareholders of the Company (the “**Shareholders**”) should note that:

- (i) If a Shareholder who has not completed and lodged the Original Proxy Form and wishes to attend the AGM by proxy, the Shareholder is required to complete and duly lodge the Revised Proxy Form at the Company’s registered office at 41st Floor, China Resources Building, 26 Harbour Road, Wanchai, Hong Kong not less than 48 hours before the time for holding the AGM (i.e. by 3:30 p.m. on 28 May 2024) or any adjournment thereof. In this case, the Original Proxy Form should not be lodged.
- (ii) If a Shareholder who has already lodged the English version of the Original Proxy Form with the Company’s registered office but has not subsequently completed and lodged the Revised Proxy Form not less than 48 hours before the time for holding the AGM (i.e. by 3:30 p.m. on 28 May 2024) or any adjournment thereof, then the English version of the Original Proxy Form will be deemed as valid and effective to the fullest extent.
- (iii) If a Shareholder who has already lodged the Chinese version of the Original Proxy Form with the Company’s registered office but has not subsequently completed and lodged the Revised Proxy Form not less than 48 hours before the time for holding the AGM (i.e. by 3:30 p.m. on 28 May 2024) or any adjournment thereof, then the Original Proxy Form will be deemed as the valid proxy form returned by the Shareholder, save and except for the ordinary resolutions numbered 3(4) and 3(5), the proxy duly appointed by the Shareholder in the Original Proxy Form will be entitled to vote for or against the resolutions at his or her own discretion as if no indication had been made to these ordinary resolutions numbered 3(4) and 3(5).

- (iv) If a Shareholder who has already lodged the Original Proxy Form (either in English or Chinese version) and subsequently completed and duly lodged the Revised Proxy Form not less than 48 hours before the time for holding the AGM (i.e. by 3:30 p.m. on 28 May 2024), then the Revised Proxy Form will supersede and replace the Original Proxy Form previously lodged by the Shareholder, and the Revised Proxy Form will be treated as the valid proxy form lodged by the Shareholder.
- (v) Completion and delivery of the Original Proxy Form and/or the Revised Proxy Form will not preclude Shareholders from attending and voting in person at the AGM or at any adjourned meeting should they so wish.

By order of the Board
China Resources Pharmaceutical Group Limited
Han Yuewei
Chairman

Hong Kong, 28 May 2024

As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong, Mr. Tao Ran and Mdm. Deng Rong as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.